What is PTC Therapeutics's gain loss on modification of lease?

PTC Therapeutics (PTCT) reported gain loss on modification of lease of $2.69M in Q4 2025.

How has PTC Therapeutics's gain loss on modification of lease changed year-over-year?

PTC Therapeutics's gain loss on modification of lease increased by 97.2% year-over-year, from $1.37M to $2.69M.

PTC Therapeutics PTCT Gain Loss On Modification Of Lease

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept ptct:GainLossOnModificationOfLease.

The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's gain loss on modification of lease.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's gain loss on modification of lease?: PTC Therapeutics (PTCT) reported gain loss on modification of lease of $2.69M in Q4 2025.
How has PTC Therapeutics's gain loss on modification of lease changed year-over-year?: PTC Therapeutics's gain loss on modification of lease increased by 97.2% year-over-year, from $1.37M to $2.69M.